Intrexon | XON - Fremdkapital





Fremdkapital Veränderung Datum
Agenus USD 169.66M 146.06M 2025-12
Alaunos Therapeutics USD 4.47M 5.85M 2022-06
Amgen USD 50B 2.43B 2025-12
Arrowhead Research USD 538.1M 323.22M 2025-12
AstraZeneca USD 26.14B 19.58B 2025-12
Bristol-Myers Squibb USD 42.85B 1.62B 2025-12
Gilead Sciences USD 22.14B 5M 2025-09
GlaxoSmithKline GBP 14.71B 186M 2025-12
Heron Therapeutics USD 140.64M 975K 2025-12
Incyte USD 30.2M 5.17M 2025-12
Intrexon USD 0 198.67M 2024-06
Karyopharm Therapeutics USD 278.22M 278.22M 2025-12
Ligand Pharmaceuticals USD 445.49M 445.44M 2025-09
MacroGenics USD 70M 256K 2025-12
MannKind USD 548.44M 244.79M 2025-12
Merck USD 39.97B 6B 2025-09
Novartis USD 29.59B 5.35B 2025-12
Rigel Pharmaceuticals USD 0 0 2024-09
Roche Holding CHF 27.43B 966M 2025-12
Sangamo BioSciences USD 0 0 2022-06
Thermo Fisher Scientific USD 35.85B 4B 2025-12
Veracyte USD 0 0 2025-03
Xencor USD 76.48M 11.29M 2025-12